Document:

Amendment No. 1 to Product Development and Commercialization Agreement

 Exhibit 10.12 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 AMENDMENT NO. 1 
 to

 PRODUCT DEVELOPMENT AND 
 COMMERCIALIZATION AGREEMENT 
 This
Amendment No. 1 (“Amendment”) to that certain PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) entered into and made effective as of the 22nd day of August, 2006 by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043
(“ChemoCentryx”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as
“GSK”), collectively, the “Parties”, is hereby entered into by the Parties with an Amendment effective date of September 30th, 2007 (the “Amendment Effective Date”). All capitalized terms not
expressly defined in this Amendment shall have the meanings given to them in the Agreement. 
 The Parties agree to amend and do hereby amend the
Agreement as follows: 
 A. Amendments Pertaining to Addition of a Celiac CCR9 PoC Trial 
 1. The following new Section 1.135 is added to the Agreement: 
 1.135 “Celiac CCR9 PoC Trial”
shall mean a Phase 2 Clinical Trial of a Collaboration Compound targeting CCR9 that is designed in accordance with Exhibit 1, which is attached hereto and is hereby incorporated by reference, as has been mutually agreed by the Parties for a
Celiac Indication (as defined under Section 1.136). Exhibit 1 shall include, and incorporate by reference, the memorandum of understanding and protocol covering such Phase 2 Clinical Trial. 
 2. The following new Section 1.136 is added to the Agreement: 
 1.136 “Celiac Indication” means an autoimmune intestinal disorder typically triggered by a specific food component called gluten (which is found in all forms of wheat, rye, barley and other related grains).

 3. Section 2.3.5 is hereby amended and restated in its entirety as follows (newly added text in bold and underlined): 
 2.3.5 Decision Making Regarding Indications. Notwithstanding Sections 2.3.4(a) and (b), with respect to each Development Candidate nominated by the JSC, and
in the course of such nomination process, the Parties shall mutually determine which potential Indication(s) to pursue for such Development Candidate and the related set of Progressed 

 Collaboration Compounds, (other than CCX282 and CCX282 Back-up Compounds for which ChemoCentryx shall have the right to
pursue in Crohn’s Disease, in asthma as reflected in the Asthma CCR9 PoC Trial and in the Celiac Indication as reflected in a Celiac CCR9 PoC Trial as provided for in this Agreement). Accordingly, no Indication shall
be pursued by ChemoCentryx under this Agreement with respect to any such Development Candidate or Progressed Compound without the prior mutual agreement of both Parties, through the JSC. In determining which Indication to pursue, the JSC shall take
into consideration the estimated costs and possible trial design of the PoC Trial for such Indication for such Development Candidate, in addition to the relevant scientific, medical, safety and commercial considerations. 
 4. Section 3.6.3 is hereby amended and restated in its entirety as follows (newly added text in bold and underlined): 
 3.6.3 Indications. At the time of the JSC decision regarding nomination of a potential Development Candidate targeting a given Collaboration Target, the
Parties, through the JSC, shall mutually determine which potential Indication(s) to pursue for such proposed Development Candidate and the related set of Progressed Collaboration Compounds. Notwithstanding the foregoing, the Parties agree that
ChemoCentryx shall have the right to pursue CCX282 and CCX282 Back-up Compounds for CCR9, in Crohn’s Disease, in asthma as reflected in the Asthma CCR9 PoC Trial and in the Celiac Indication as reflected in a Celiac CCR9 PoC
Trial as provided for in this Agreement. In the event the JSC cannot agree on such Indications, it shall proceed as provided in Section 2.3.5. 
 5. Section 3.7.2 is hereby amended by adding the following new paragraph (e): 
 3.7.2(e) Celiac CCR9 PoC Trial.
ChemoCentryx shall also have the right, in its sole discretion, to conduct a Celiac CCR9 PoC Trial; provided, however, that GSK shall have the right to review and comment on the design of any Celiac CCR9 PoC Trial before it is finalized, and GSK
must approve the final applicable PoC Criteria and the final study design and content of such Celiac CCR9 PoC Trial prior to initiation, such approval not to be unreasonably withheld. The Parties understand and acknowledge that it is possible that a
Celiac CCR9 PoC Trial may be completed prior to the PROTECT-1 Trial or the Asthma CCR9 PoC Trial, and therefore GSK may first have the opportunity to exercise its Product Option with respect to CCX282 in accordance with Section 4.3.1(b) based
upon data resulting from such Celiac CCR9 PoC Trial rather than from the PROTECT-1 Trial or the Asthma CCR9 PoC Trial. Regardless of whether GSK exercises its Product Option at such time for the Celiac CCR9 PoC Trial or at a different time under
Section 4.3.1(b), ChemoCentryx will continue the PROTECT-1 Trial unless terminated for good scientific, safety or ethical reasons. 
 6.
Section 3.8.1 is hereby amended and restated in its entirety as follows (newly added text in bold and underlined): 
 3.8.1 For CCX282.
Unless and until GSK exercises its Product Option with respect to CCX282 or a CCX282 Back-up Compound, promptly after the conduct of each of the following (a) the PROTECT-1 Induction Phase, (b) the PROTECT-1 Maintenance
Phase, 

  

 2 

 
(c) a Celiac CCR9 PoC Trial, and (d) the Asthma CCR9 PoC Trial, as applicable, if ChemoCentryx determines that CCX282 or the CCX282
Back-up Compound meets the PoC Criteria therefor, ChemoCentryx shall promptly notify GSK, in writing, of such event. The JSC will, at a special ad hoc meeting to be scheduled, confirm that CCX282 or the CCX282 Back-up Compound
meets such PoC Criteria and that the PoC Trial has successfully met the relevant endpoints. Following such confirmation, GSK shall have the right to exercise its Product Option with respect to CCX282 or the CCX282 Back-up Compound in
accordance with Section 4.3.1(b) and Article 4. Where GSK does not so elect to exercise its Product Option at the time point referenced in clause (a) above, as provided in Section 4.3, then following the time point referenced in
clause (b), (c), or (d) above, if ChemoCentryx again determines that CCX282 or a CCX282 Back-up Compound meets the PoC Criteria, ChemoCentryx shall promptly notify GSK, in writing, of such event. The JSC will, at a
special ad hoc meeting to be scheduled, confirm that CCX282 or a CCX282 Back-up Compound meets such PoC Criteria. Following such confirmation, GSK shall again have the right to exercise its Product Option with respect to CCX282
or the CCX282 Back-up Compound in accordance with Article 4 and Section 4.3.1(b). Such process shall again continue with respect to all four (4) time points described in clauses (a), (b), (c) and
(d) above, as and to the extent ChemoCentryx conducts such PoC Trials in accordance with the provisions of this Agreement, and CCX282 or a CCX282 Back-up Compound meets the PoC Criteria with respect to the
PoC Trial referenced therein. GSK shall thus have a total of up to four (4) opportunities to exercise its Product Option with respect to CCX282 or a CCX282 Back-up Compound in accordance with
Section 4.3.1(b), and the failure by GSK to exercise any of such opportunities shall not count against GSK’s Product Options, unless and until all of such opportunities with respect to CCX282 or a CCX282 Back-up Compound
arising hereunder are declined by GSK. 
 7. Section 4.2.2 is hereby amended and restated in its entirety as follows (newly added text in bold and
underlined): 
 4.2.2 For CCX282 or a CCX282 Back-up Compound. Notwithstanding the foregoing
Section 4.2.1, a new and different PoC Trial Report for CCX282 or a CCX282 Back-up Compound shall be delivered to GSK within sixty (60) days of the JSC having determined that CCX282 or a CCX282 Back-up Compound
meets the PoC Criteria and has successfully met the endpoints for the PoC Trial in each of the following situations: (a) the PROTECT-1 Induction Phase, (b) the PROTECT-1 Maintenance Phase, (c) a Celiac CCR9 PoC Trial, and
(d) the Asthma CCR9 PoC Trial, and each such PoC Trial Report shall include all the preclinical and clinical data showing that the clinical endpoints have been achieved demonstrating the successful outcome of the respective portion of
the PROTECT-1 Trial or a Celiac CCR9 PoC Trial or the Asthma CCR9 PoC Trial, as the case may be. 
 8. Section 4.3.1(b) is hereby
amended and restated in its entirety as follows (newly added text in bold and underlined): 
 4.3.1(b) For CCX282 or a CCX282 Back-up
Compound, GSK shall have a total of four (4) potential opportunities to exercise its Product Option, as follows. The Product 

  

 3 

 
Option for CCX282 shall be exercisable by GSK, at its sole discretion, upon each of the following occasions: within ninety (90) days (as may be extended
pursuant to Section 4.3.1(a) above) after ChemoCentryx provides to GSK a PoC Trial Report with the preclinical and clinical data showing that clinical endpoints have been successfully met demonstrating the successful outcome of (i) the
PROTECT-1 Induction Phase, (ii) the PROTECT-1 Maintenance Phase, (iii) a Celiac CCR9 PoC Trial, if conducted, and (iv) the Asthma CCR9 PoC Trial, if conducted, for CCX282. In the event that GSK declines such exercise on
the first or on the first three of such four opportunities to exercise its Product Option for CCX282 or a CCX282 Back-up Compound, such election(s) to decline to exercise at such first three opportunities
shall not count against any of GSK’s Product Options, and GSK shall still retain a fourth opportunity to exercise its Product Option, if and when a fourth opportunity is triggered as described above. The Parties
understand and agree that such a third and/or fourth opportunity may never be available in the event that ChemoCentryx elects not ever to conduct the Asthma CCR9 PoC Trial and/or a Celiac CCR9 PoC Trial. In addition, for
clarity, the Parties understand and agree that CCX282 and its two Back-up Compounds collectively constitute only one Option Compound under this Agreement and only one Product Option hereunder, regardless of the total number of times that
GSK’s Product Option is triggered for such set of Progressed Compounds by completion of successful PoC Trials for CCX282 and/or any of its Back-up Compounds, and regardless of the number of different Indications, formulations, methods of
delivery, prodrugs, esters, salts, crystalline polymorphs, hydrates or solvates thereof which are Developed hereunder for such Progressed Compounds, taken collectively. It being understood, however that ChemoCentryx shall have no obligation to
pursue any such different Indications, formulations, and the like. 
 B. Amendments Pertaining to Co-Development and Co-Promotion Rights for the Celiac
Indication and to ChemoCentryx’ Change of Control 
 1. Section 5.2.1 is hereby amended and restated in its entirety as follows (newly
added text in bold and underlined): 
 5.2.1 Generally. Following GSK’s exercise of its Product Option, but not later than twelve
(12) months prior to the first expected NDA filing for such Product Candidate targeting CCR9, GSK shall provide to ChemoCentryx a detailed development plan and associated budget for the conduct of the Dossier Studies for such Licensed Product
targeting CCR9 (the “Development Plan and Budget”). ChemoCentryx shall have the right to review and comment upon such Development Plan and Budget, and shall have the option (the “Co-Development Option”) within
ninety (90) days following receipt of the final Development Plan and Budget to co-fund Dossier Studies for any or all of (i) the Regulatory Approval of Crohn’s Disease only (the “CD Development Option”); (ii) the
Regulatory Approval of Crohn’s Disease as well as ulcerative colitis (the “CD/UC Development Option”); or (iii) the Regulatory Approval of the Celiac Indication (the “Celiac Development Option”). In the event that GSK
subsequently significantly amends the Development Plan and Budget to include for the first time the ulcerative colitis Indication or the Celiac Indication by the addition of new Clinical Studies targeting the ulcerative
colitis Indication or the Celiac Indication, GSK shall promptly 

  

 4 

 
notify ChemoCentryx of such amendment, and ChemoCentryx shall have an additional ninety (90) days within which to review and comment upon such
amended Development Plan and Budget and exercise the CD/UC Development Option or the Celiac Development Option, at its discretion. Depending on its election, ChemoCentryx shall receive additional royalties as set forth in
Section 6.6.5(a) or Section 6.6.5(b), as applicable. The royalty rate increases resulting from exercise of the Celiac Development Option will be the same as for exercise of the CD Development Option. For clarity, the Parties
understand that ChemoCentryx’s Co-Development Option under this Agreement shall apply only to CCR9. 
 2. Section 5.2.2 is hereby amended and
restated in its entirety as follows (newly added text in bold and underlined): 
 5.2.2 Reimbursement of GSK Costs. Upon exercise of the
Co-Development Option, ChemoCentryx shall pay to GSK a one time cash payment equal to thirty-five percent (35%) of the GSK Incurred Costs for any of the Crohn’s Disease Dossier Studies, the Crohn’s Disease and Ulcerative Colitis
Dossier Studies, or the Celiac Disease Dossier Studies, depending on whether ChemoCentryx exercised the CD Development Option, the CD/UC Development Option or the Celiac Development Option, respectively. In addition,
following exercise of the Co-Development Option, ChemoCentryx shall reimburse, on a quarterly basis, in arrears, thirty-five percent (35%) of all applicable Dossier Study Costs with respect to such Licensed Product through and including
approval of the NDA. 
 (a) In the event that the actual Dossier Study Costs are reasonably expected to exceed [***] percent ([***]%)
of the estimated costs for such studies as set forth in the Development Plan and Budget, ChemoCentryx shall have the option to either continue to co-fund such additional Dossier Study Costs, or to elect, in writing, to withdraw from its
co-development participation in such Licensed Product entirely, or with respect to the Indication at issue, as the case may be, in which case GSK shall refund all Dossier Study Costs and all GSK Incurred Costs then paid to GSK to date by
ChemoCentryx (the “Repayment Amount”) in four (4) quarterly payments over the course of the following twelve (12) months. 
 (b) In addition, in the event that ChemoCentryx is unable to make its ongoing co-funding payments due to lack of financial wherewithal, but not due to any negative clinical trial results or lack of progress or any Third Party
commitment or any change in the competitive environment, then ChemoCentryx shall have the right to elect, upon written notice to GSK, to withdraw from its co-development participation in such Product Candidate entirely, in which case GSK shall
refund to ChemoCentryx the Repayment Amount, in the form of a royalty on U.S. Net Sales, as follows. In the event that ChemoCentryx is more than one hundred and twenty (120) days late on any co-funding payment due hereunder, GSK shall have the
right to terminate ChemoCentryx’s right to participate in the Co-Development by default). GSK shall pay to ChemoCentryx, 
  

	***	 Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 5 

 in addition to the royalties otherwise owed under
Section 6.6.1 or 6.6.2, a royalty of [***] percent ([***]%) on worldwide Net Sales of such Licensed Product, [***] the “Royalty
Differential” equals [***]. As used herein, the “Royalty Differential” shall mean the difference between the amount that would have been paid on such worldwide Net Sales pursuant to the rates set forth in Section 6.6.1 or 6.6.2,
and the amounts paid pursuant to the higher rates set forth in Section 6.6.5(a) or 6.6.5(b). Thereafter, ChemoCentryx shall be paid the lower royalty on worldwide Net Sales in accordance with Section 6.6.1 or 6.6.2. 
 (c) For clarity, ChemoCentryx’s Co-Development Options shall be available to ChemoCentryx only with respect to each Product Candidate
targeting CCR9 and which is under Development for Crohn’s Disease and/or Ulcerative Colitis, or for the Celiac Indication. 
 3. The
following new Section, 5.2.3, is hereby added as follows: 
 5.2.3 Change in
Control. In the event that ChemoCentryx undergoes a Change in Control Event, ChemoCentryx’ Co-Development Option under Section 5.2 shall [***]. For the purposes of this Section 5.2.3, a “Change in Control Event” means:
(i) a merger or consolidation of ChemoCentryx with any pharmaceutical or biotechnology or other life sciences company in which (A) ChemoCentryx is not the surviving corporation and (B) the holders of ChemoCentryx securities
immediately prior to the merger or consolidation receive less than [***] percent ([***]%) of the combined voting power entitled to vote in the election of
the board of directors of the surviving entity by reason of their ownership of ChemoCentryx securities; or (ii) an acquisition which results in beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or
comparable successor rule) by any person, entity or group within the meaning of Section 13(d) or 14(d) of the Exchange Act, or any comparable successor provisions (excluding any employee benefit plan, or related trust, sponsored or maintained
by ChemoCentryx or a subsidiary of ChemoCentryx or other entity controlled by ChemoCentryx) of securities of ChemoCentryx representing at least [***] percent ([***]%) of the combined voting power entitled to vote in the election of the board of
directors; provided, however that clauses (i) and (ii) of this Section 5.2.3 shall not apply to a merger effected exclusively for the purpose of changing the domicile of ChemoCentryx. In no event shall “Change of Control”
include any transaction in which the Company or its successor(s) issues securities to financial investors solely for capital raising purposes, provided that the principal business of any such financial investors is not the development and/or
commercialization of pharmaceutical, biotech or biopharmaceutical products. 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 6 

 4. Section 5.6.1 is hereby amended and restated in its entirety as follows: 
 5.6.1 Exercise of Co-promotion Right. 
 (a) Subject to
subsections 5.6.1(a)(i) and 5.6.1(a)(ii) herein, prior to and up to the date of filing of an NDA for each Co-Developed Product, ChemoCentryx shall have the option to co-promote each such Co-Developed Product (the “Co-promotion Right”), in
the U.S. only, by providing up to fifty percent (50%) of the requisite detailing effort (as determined in good faith by GSK) to agreed-upon specialist physicians as set forth in the Product Marketing Plan, pursuant to a definitive co-promotion
agreement which will incorporate and be consistent with all of the terms and conditions described in this Section 5.6 (including, without limitation, subsections 5.6.1(a)(i) and 5.6.1(a)(ii) herein) and all other relevant provisions of this
Agreement (the “Co-Promotion Agreement”), the full set of terms and conditions for such definitive co-promotion agreement will be in accordance with a written commercialization plan to be prepared by GSK’s sales and marketing
organization (the “Product Marketing Plan”). 
 (i) If ChemoCentryx exercises its Co-promotion Right under
Section 5.6.1(a) for a given Co-Developed Product as to which ChemoCentryx already exercised its CD Development Option or the CD/UC Development Option (as set forth under Sections 5.2.1(i) and 5.2.1(ii), respectively), then ChemoCentryx shall
also shall have the option, exercisable upon written notice to GSK, to co-promote the same Co-Developed Product (i.e., such Co-Developed Product is the same molecule as the product as to which ChemoCentryx is exercising its co-promotion option) for
the Celiac Indication in the U.S. (following approval therefor by the FDA) regardless of whether ChemoCentryx has as of such time exercised its Celiac Development Option or not with respect to such Co-Developed Product, by providing up to fifty
percent (50%) of the requisite detailing effort (as determined in good faith by GSK) to gastrointestinal specialist physicians, pursuant to the relevant Co-Promotion Agreement then in effect (where such Co-Promotion Agreement has as of such
time been executed), which Co-Promotion Agreement shall be amended to include the co-promotion of such same Co-Developed Product for the Celiac Indication. For clarity, such right to co-promote such Co-Developed Product for the Celiac Indication as
set forth under this Section 5.6.1(a)(i) shall be available to ChemoCentryx even if ChemoCentryx has not exercised its Celiac Development Option as to such specific Co-Developed Product. 
 (ii) If ChemoCentryx does not exercise the CD Development Option or the CD/UC Development Option (as set forth under Sections 5.2.1(i) and 5.2.1(ii),
respectively) but does exercise the Celiac Development Option, ChemoCentryx shall have the right to exercise, at its sole discretion, its Co-Promotion Right to co-promote such Co-Developed Product for the Celiac Indication in the U.S.; provided that
ChemoCentryx is able to demonstrate to GSK’s reasonable satisfaction, using commercially reasonable market analysis and projections, that the potential market for such Co-Developed Product for the Celiac Indication in the U.S. is equal to or
exceeds 

  

 7 

 
[***] Dollars ($[***]). In any event, ChemoCentryx shall have
the right to exercise, at its sole discretion, its Co-promotion Right to co-promote such Co-Developed Product for the Celiac Indication in the U.S. three (3) months after the first complete calendar year in which actual Net Sales for such
Co-Developed Product in the U.S. equal at least [***] dollars ($[***]), but only where such sales level is achieved prior to or at the end of the fourth full calendar year following the first launch of the Co-Developed Product in the U.S.
Under such an exercise of its Co-Promotion Right hereunder, ChemoCentryx may provide up to fifty percent (50%) of the requisite detailing effort (as determined in good faith by GSK) to gastrointestinal specialist physicians, pursuant to the
Co-Promotion Agreement to be entered into by the Parties. 
 (b) If ChemoCentryx exercises its Co-promotion Right prior to or upon NDA
filing for such Co-Developed Product, such co-promotion shall be in accordance with the Product Marketing Plan and using only GSK-approved promotional messages and materials, in accordance with Section 5.5.2 of this Agreement which shall be
updated and amended as necessary upon ChemoCentryx’s exercise of the Co-Development Option with respect to such Product Candidate, and in accordance with all applicable laws and regulations (including without limitation those promulgated by the
FDA and the Division of Drug Marketing and Communications). ChemoCentryx shall be responsible for ensuring that its sales force representatives are of an acceptable standard in knowledge, experience and skills as judged by GSK’s Sales
Management Organization. ChemoCentryx will ensure that its sales force representatives shall be trained to the same level and with consistent materials as GSK’s own sales force representatives, and achieve similar pass rates in sales training
exams as determined by GSK at the time of such training. ChemoCentryx’s sales force representatives shall attend, as appropriate in view of GSK’s policies, such training seminars as are held for GSK’s own sales force representatives.
Notwithstanding such co-promotion rights, GSK shall not be restricted in its promotional and selling efforts to any specialist or general practice physicians, and ChemoCentryx shall have no rights to detail or otherwise promote Licensed Products to
family practitioners, internal medicine or any other general practice physicians. It is understood that ChemoCentryx’s Co-promotion activities shall be supplemental to and consistent with, the promotion capabilities of GSK. For clarity,
ChemoCentryx’s Co-Promotion Rights shall only apply to Co-Developed Products. 
 C. Amendments Pertaining to the Governance of Co-Development
Activities 
 1. Section 2.3.4 (b) is hereby amended and restated in its entirety as follows (newly added text in bold and underlined) 

 (b) GSK Decisions. Except as otherwise expressly set forth in this Agreement, GSK shall have final decision-making authority with respect to all
decisions relating to: 
 (i) its decision whether to exercise its Product Option; 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 8 

 (ii) the development of Product Candidates after exercise by GSK of its Product Option with respect to
same, or the co-development (pursuant to the exercise by ChemoCentryx of its Co-Development Option under Sections 5.2 and 5.3) of Product Candidates (provided; however, that the governance and dispute resolution process for activities and
decisions with respect to Co-Developed Products shall be in accordance with the process as described in Schedule 5.3, and not as described in the preamble of this Section 2.3.4);  
 (iii) the Product Candidate Commercialization Program; and 
 (iv) all matters pertaining to commercialization and marketing of Licensed Products after exercise of its Product Option. 
 2. Schedule 5.3 is hereby amended and restated in its entirety as follows: (changes shown in bold and underlined text). 
 SCHEDULE 5.3 
 [***] 
 (The remainder of page 9 and page 10 are redacted.) 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 9 

 D. Amendments Pertaining to the Joint Steering Committee and Early Development Program 
  

	1.	The first paragraph of Section 2.3 (but not any of Sections 2.3.1 through 2.3.8 except as expressly stated below) is hereby amended and restated in its entirety as
follows: 

 2.3 The Joint Steering Committee. Promptly and in any event within
ninety (90) days after the Effective Date, the Parties shall establish a committee (the “Joint Steering Committee” or “JSC”) as more fully described in Sections 2.3.1 through 2.3.8 of this Section 2.3. The
JSC shall have review and oversight responsibilities for all research and Development activities performed hereunder during the Research Term and with respect to each Early Development Program prior to exercise of a Product Option by GSK, and shall
serve as a vehicle to facilitate the conduct of information between the Parties with respect to any commercialization activities and the Product Candidate Commercialization Program, in each case as more specifically provided herein. Each Party
agrees to keep the JSC informed of its progress and activities within the Research Program, each Early Development Program, and each Product Candidate Commercialization Program, respectively. At its sole discretion, ChemoCentryx may terminate its
participation in the JSC upon the earlier of (a) the date on which GSK exercises its Product Option for the sixth (6th) Option Compound,
(b) the date on which the JSC agrees to terminate the Research Program and all Early Development Programs then in progress without either the JSC or GSK nominating a substitute Backup Compound for the lead Development Candidate against
Collaboration Targets being developed under such Early Development Programs; or (c) ten (10) years from the Effective Date. In the event that ChemoCentryx elects to terminate its participation on the JSC pursuant to subsection
(c) herein, the Parties understand and agree that (i) if at such time there is on-going an Early Development Program as of such election date, such Early Development Program shall remain in effect and continue (unless otherwise terminated
in accordance with Section 3.2.3) and remain subject to the terms and conditions of this Agreement; and (ii) GSK shall assume sole decision-making authority with respect to all decisions otherwise delegated to the JSC under
Section 2.3.7 with respect to any such continuing Early Development Program. 
 2. Section 2.3.4(a) Decision Making, ChemoCentryx
Decisions, clause (i) is hereby restated in its entirety as follows (newly added text in bold and underlined): 
 (i) the Research Program and
Research Plan and Development Candidate Criteria for each Collaboration Target;  
 3. Section 2.3.7 Responsibilities of the JSC,
subsection (a) is hereby restated in its entirety as follows (newly added text in bold and underlined): 
 (a) review the overall progress of
ChemoCentryx’s efforts to discover, identify, optimize and develop Collaboration Compounds, Development Compounds, Development Candidates and Option Compounds and to establish, review, update and approve the  

  

 11 

 
Development Candidate Criteria for each Collaboration Target (subject to Section 2.3.4(a)); 
 4. Section 3.2.3 is hereby amended and restated in its entirety as follows (newly added text in bold and underlined): 
 3.2.3 Early Development Program Term. Each Early Development Program will start at the earlier of
commencement of activities under such Early Development Program or adoption of the Early Development Plan by the JSC, and will terminate upon the earlier of (a) the date on which GSK exercises its Product Option for the sixth (6th) Option Compound, (b) the date on which the JSC agrees to terminate such Early Development Program without either the JSC or GSK nominating a
substituting Backup Compound for the lead Development Candidate against such Collaboration Target; or (c) ten (10) years from the start of such Early Development Program (the “Early Development Program Term”), unless
earlier terminated pursuant to other applicable provisions of this Agreement. Notwithstanding anything to the contrary herein, ChemoCentryx’ diligence obligations shall apply only to the first five (5) years of any such Early
Development Program, but in any event shall not apply, as to any Early Development Program, after ten (10) years following the initiation of the first Early Development Program. 
 5. Section 1.94, “PoC Criteria” is hereby amended to change the term “Proof of Concept” in the first sentence to “proof of
concept”. 
 E. Amendments Pertaining to the Exchange of Information. 
 1. Section 3.10 is hereby amended and restated in its entirety as follows: 
 3.10 Exchange of
Information. Subject in all cases to the provisions of Article 9, each of GSK and ChemoCentryx will share any Information directly relating to Collaboration Compounds and/or Product Candidates that is generated in the course of the Parties’
activities hereunder with the JSC, on an ongoing basis, in order to facilitate GSK’s decision-making in connection therewith and to monitor the obligations of the Parties. All such exchanges of Information shall be coordinated by the Project
Directors. In addition, in the event that ChemoCentryx terminates its participation on the JSC pursuant to Section 2.3, the Parties will share such Information, and GSK will share with ChemoCentryx any Information otherwise shared with or
through the JSC, directly through each of their respective Project Directors. The provision of all such Information shall be performed in a timely matter to accommodate all regulatory deadlines and ensure compliance with the timelines set forth in
any agreed plan. 
 F. Except as expressly modified by this Amendment, all the other provisions of the Agreement shall remain unchanged and in full force
and effect. 
  

 12 

 IN WITNESS WHEREOF, each of the Parties has caused this Amendment to be duly executed by its duly authorized
representatives as of the Amendment Effective Date. 
  

			
	GLAXO GROUP LIMITED
		
	By:	 	 /s/ V.A. Whyte

	Name:	 	 V.A. Whyte

	Title:	 	 Assistant Secretary

		
	Date:	 	8 November 2007
	
	CHEMOCENTRYX, INC.
		
	By:	 	 /s/ Thomas J. Schall

	Name:	 	 Thomas J. Schall, Ph.D.

	Title:	 	 President & CEO

		
	Date:	 	8 November 2007

  

 13 

 Exhibit 1 
 Celiac CCR9 Trial Design 
 MEMORANDUM OF UNDERSTANDING 
 [***] 
 Between: ChemoCentryx Inc.
(CCX) & GlaxoSmithKline Plc. (GSK) 
 Date: 30th May 2007 
 [***] 
 (The remainder of this page and page 15 are redacted.) 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 14 

 [***] 
  

			
	[***]:	  	[***]
		
	[***]:	  	[***]
		
	[***]:	  	[***]
		
	Indication:	  	Celiac Disease
		
	Sponsor:	  	ChemoCentryx, Inc.
		
	Development Phase:	  	II
		
	Sponsor:	  	 ChemoCentryx, Inc.
 850 Maude Avenue
 Mountain View
 CA 94043

		
	 Sponsor Signatory:
  
 [***]:
	  	 Pirow Bekker, MD PhD
  
 [***]

		
	[***]:	  	[***]
		
	Approval Date:	  	29th June 2007
		
	[***]:	  	[***]

 Confidential 
 The information contained herein is the property of the Sponsor and may not be reproduced, published, or disclosed to others without written authorization of the Sponsor 
 This study will be conducted according to the principles of Good Clinical Practice as described in International Conference on Harmonization guidelines,
including the archiving of essential documents 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 16 

 [***] 

					
	 _____________________________________
	  		  	_____________
	 Principal Investigator
  
  
	  		  	Date
	_____________________________________	  		  	
	Printed Name	  		  	
		  		  	

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 17 

 [***] 

					
	______________________________________	  		  	_____________________________
	Pirow Bekker, MD PhD	  		  	 Date

	Vice President, Medical and Regulatory Affairs	  		  	

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 18 

 [***] 
 (This page and page 20 are redacted.) 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 19 

 Synopsis 
  

					
	 Name of Sponsor
  
 ChemoCentryx, Inc
	    	[***]	 	[***]
	 		 
	 [***]
	    	 	 	 
	 		 
	 [***]
	    	 	 	 
	 		 
	 [***]
	    	 	 	 
	 		 
	 [***]
	    	 Phase of Development:
  
             Phase
II
	 	 
	 
	 [***]
  
 Patients with celiac disease suffer from intolerance to gluten, an important ingredient in the daily diet, found in wheat, barley, and rye. Gluten ingestion in this
patient population causes small bowel mucosal damage. [***]. The current treatment of celiac disease involves strict adherence to a life-long gluten-free diet. Patients worldwide have expressed their need for additional
treatments.

 [***] 
 (The remainder of this page and pages 22-29 are redacted.) 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 21 

 1 Introduction 
 1.1 Background 
 Celiac disease (celiac sprue, gluten-sensitive enteropathy) is a genetically associated disorder, where the ingestion of
gluten-containing cereals wheat, barley and rye results in small intestinal mucosal inflammation, villous atrophy and crypt hyperplasia. Today it is understood that the nature of celiac disease is much more complex than simple intestinal
malabsorption, which in fact is a feature now no longer essential for the diagnosis. Furthermore, the ingestion of gluten-containing cereals can also induce manifestations outside the gut (Mäki and Collin 1997). Recent population-based
screening studies have shown the disease to be highly prevalent; approximately 1% of the populations both in Europe and the United States suffer from celiac disease (Mäki et al. 2003, Fasano et al. 2003, West et al. 2003, Bingley et al. 2004).

 The only accepted gold standard for celiac disease diagnosis is the finding of gluten-induced small intestinal injury (Walker-Smith et al. 1990, American
Gastroenterology Association 2006, Rostom et al. 2006). Clinical findings are usually equivocal: newly diagnosed patients eating normal gluten-containing food may, in some cases, have only vague gastrointestinal symptoms whereas in others symptoms
may be severe; in people with extra-intestinal manifestations gastrointestinal symptoms may be absent; or the disease may even be clinically silent. One feature that is common to all however is the manifest gluten-sensitive small intestinal mucosal
lesion, villous atrophy and crypt hyperplasia. In untreated celiac disease the degree of malabsorption is determined by the length of functionally impaired bowel and the presence of symptoms does not relate at all to the histological features of the
proximal biopsy (MacDonald et al. 1964, Marsh and Crowe 1995). This also explains why oral glucose tolerance tests, fecal fat excretion, D-xylose excretion tests, hematologic investigations, and radiologic examination of the small
bowel failed to distinguish patients with suspected malabsorption from those with or without mucosal atrophy and, thus, frequently gave misleading results (Sanderson et al. 1975). Based on the current literature in 2002, in a review article in the
New England Journal of Medicine, it was concluded that only patients with extensive and severe enteropathy will have evidence of steatorrhea and increased intestinal permeability; in patients with mild-to-moderate enteropathy these tests will remain
normal and therefore these tests are no longer important tools in cases of suspected celiac disease or while monitoring dietary treatment (Farrell and Kelly 2002). Furthermore, recent guidelines and management models for celiac disease diagnosis and
treatment in the USA no longer recommend these functional studies (Hill et al. 2005, Rostom et al. 2006). Instead, during the last two decades, highly sensitive and specific gluten-dependent serum autoantibody tests have been used for celiac disease
case finding, population-based screening studies, monitoring the gluten-free diet, and measurement of mucosal relapse on gluten challenge (Mäki et al. 1984, Mäki et al. 1989, Mäki et al. 1991 a, Dieterich et al. 1998, Sulkanen et al.
1998, Mustalahti et al. 2002 a, Kaukinen et al. 2002, Mäki et al. 2003, Korponay-Szabo et al. 2005, Collin et al 2005, Hill et al. 2005, Holm et al. 2006, Raivio et al. 2006, Rostom et al. 2006 ). As reviewed by Mäki (1995), antibody
titers correlate well with the small intestinal mucosal status. 
 As reviewed by Marsh and Crowe (1995), time-course studies of gluten challenges provide
clear evidence of an inflammatory process, a dose-dependent accumulation of lymphocytes to the epithelium during the lower-dose challenges. Upon further challenge, crypt hyperplasia occurs and lastly, villous effacement is seen (flat mucosal
lesion). 
  

 30 

 The Celiac Disease Study Group in Tampere, Finland, has extensively used small intestinal mucosal morphometric analyses
to determine ingested wheat-, rye-, and barley- (gluten)-induced mucosal inflammation and mucosal architectural changes in early developing celiac disease, in active and clinically silent disease, during treatment follow-up of patients when the
mucosa is healing (Mäki et al. 1991b, Holm et al. 1992, Holm 1993, Iltanen et al. 1999 a, b, Kaukinen et al. 1998, Kaukinen et al. 1999, Kaukinen et al. 2000, Kaukinen et al. 2001, Järvinen et al. 2003, Peräaho et al. 2003,
Järvinen et al. 2004, Collin et al. 2004 b, Kaukinen et al. 2005, Kaukinen et al. 2006 a, Salmi et al. 2006), as well as during gluten challenge (Holm et al. 2006, Kaukinen et al. 2006 b). These parameters have included determination of the
villous height/crypt depth ratio to establish manifest gluten-induced mucosal architectural change, and counting of the intraepithelial densities of all T lymphocytes (CD3-positive IELs), densities of aß+ and yd+ T cell receptor-bearing IELs, as well as evaluation of the expression of
mucosal HLA-DR to reveal gluten-induced inflammatory changes. A decrease in villous height/crypt depth ratio of > 0.5 upon gluten challenge has been regarded as clinically significant. Similarly, a 30% or higher increase in the densities
of intraepithelial CD3+ or aß+ lymphocytes has been regarded as clinically significant (Kaukinen et al. 2005). 
 A lifelong gluten-free diet is currently the only treatment for celiac disease. The alleviation of symptoms and recovery of mucosal damage are evident with a strict
gluten-free diet. It is generally agreed that a gluten-free diet should be as strict as possible. On the other hand, a diet completely devoid of gluten is probably impossible to maintain. There is also evidence in the literature that the small
intestinal mucosa does not heal upon strict diet. In one study, only 20% of patients were found to have complete healing of the mucosa (Lee et al. 2003). This may be due to persisting in situ activation of intraepithelial T cells even in
well-treated celiac patients (Olaussen et al. 2007), unintentional gluten ingestion, or poor gluten-free dietary compliance (Mayer et al. 1991, Kaukinen et al. 1999, Kaukinen et al. 2002, Collin et al. 2004 c, Viljamaa et al 2005, Rostom et al.
2006, Hischenhuber et al. 2006, Hauser 2007). It is evident that a gluten-free diet is more expensive than a so-called ‘normal’ diet; also social life and travel contribute to dietary lapses. Taken together, there is a need for alternative
treatments, ideally in the form of a safe and effective “celiac pill” (Sollid and Khosla 2004). 
 While the etiology of celiac disease remains
unknown, it is characterized by loss of immunological tolerance to wheat, rye and barley gluten in genetically susceptible individuals (reviewed in Sollid 2002, Koning et al. 2005, Alaedini and Green 2005, Jabri and Sollid 2006, and Kagnoff 2007).
There is strong evidence that celiac disease is a T-cell-mediated chronic inflammatory bowel disorder with gluten as an autoimmune trigger. CD4-effector T-cells seem to be particularly important in driving the underlying chronic inflammatory
process. The small intestinal mucosa is the tissue compartment where ingested gluten initially triggers the T-cell mediated cascade of events that result in loss of mucosal integrity, and subsequent ill health and disease. 
 It is known that the trafficking of T cells to the small intestinal mucosa is, both under homeostatic and inflammatory conditions, controlled by chemokine receptor CCR9
and its ligand CCL25 (previously known as TECK). The CCR9 receptor is expressed by most T cells in the thymus as well as in the intestine (Kunkel et al, 2000), and by a small population of T cells in the peripheral blood (Papadakis et al, 2003).
CCR9 positive T cells also express the a4ß7 integrin, which along with CCR9, is considered essential for gut-homing cells to reach their
destination (Stagg et al, 2002). Circulating CCR9 positive T cells have been shown to have a memory phenotype indicative of cells central to antigen specific responses. In the gut antigens such as gluten are processed by resident dendritic cells in
the lamina propria which then migrate to the local mesenteric 

  

 31 

 
lymph nodes. Once in the local lymph nodes, the dendritic cells present antigen to naïve lymphocytes and secrete retinoic acid (Iwata et al, 2004),
enabling the expression of the gut homing integrin a4ß7 and the chemokine receptor CCR9. These T lymphocytes, having encountered gluten antigen
are capable of trafficking to the gut under the influence of gut-expressed CCL25. Once these T cells reach the gut they are thought to play a very substantial role in the pathological response associated with gluten exposure. Use of a CCR9
antagonist to both inhibit the education of naïve lymphocytes to gluten antigen and CCR9-dependent T cell homing to the gut is a highly promising therapeutic strategy for the treatment of celiac disease. 
 [***]

 People eating an average Western diet ingest approximately 15-25 g gluten per day. In celiac disease, the onset of symptoms and signs of gluten
intolerance may occur in childhood but become evident most often only in adulthood or in the elderly after decades of gluten ingestion. It has been shown in previous clinical gluten challenge studies that older children, adolescents and young adults
with long-term treated celiac disease can tolerate well the ingestion of 10-20 g gluten per day (Mäki et al 1989, Holm et al. 2006). Also, a gluten challenge with repeated small intestinal mucosal biopsies has until fairly recently been
mandatory to establish the definite diagnosis of celiac disease, especially in children (in some parts of the world this regimen is still followed). The effect of small gluten loads on the mucosal integrity and a safe gluten threshold in treated
celiac disease is still under discussion (Peräaho et al. 2003, Collin et al. 2004 a, Catassi et al. 2006, Hischenhuber et al. 2006). In this proof-of-concept clinical trial we propose to challenge subjects with a moderate amount gluten (5g per
day for three months). The literature and our clinical experience tell us that this moderate dose of gluten should cause some mucosal deterioration and inflammation but without inducing clinical symptoms and causing resultant dropout of subjects
from the trial. This fixed daily amount of gluten corresponds to the ingestion of approximately to 2-3 slices of wheat flour-based bread per day. The drug under evaluation, to be clinically effective, should be able to significantly reduce or
prevent the mucosal deterioration caused by this 5g daily gluten challenge. 
 The ultimate goal in celiac disease clinical research is to prevent disease
and sustain health, and also to develop new therapeutic strategies, less burdensome than a strict life-long gluten-free diet (Sollid and Khosla 2004). In this way it is hoped that celiac disease patients may in the future be able to ingest foods
containing wheat, barley, and rye. 
 [***] 
 (The remainder of the document is redacted.) 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 32Clinical Research Services Agreement

 EXHIBIT 10.13 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 CLINICAL RESEARCH SERVICES AGREEMENT 
 THIS CLINICAL RESEARCH SERVICES AGREEMENT (“Agreement”) made this 12th day of October 2006 (“Effective Date”), by and between
CHEMOCENTRYX, INC., a Delaware corporation with its principal executive offices located at 850 Maude Avenue, Mountain View, CA 94043 (“Sponsor”), and KENDLE
INTERNATIONAL INC., with its principal executive offices located at 441 Vine Street, 1200 Carew Tower, Cincinnati, OH 45202 (“Kendle”). Kendle and Sponsor may each be referred to individually as a
“Party,” and collectively, as “Parties.” 
 WHEREAS, Sponsor is
engaged in the development, manufacture, distribution, and sale of pharmaceutical products; and 
 WHEREAS, Kendle is a contract research organization engaged in the business of managing clinical research programs; and 
 WHEREAS, Sponsor wishes to retain the services of Kendle to perform clinical research services in connection with the clinical research programs conducted by Sponsor, as more fully
set forth in various project specific addenda; and 
 WHEREAS, Kendle is willing to provide such
services to Sponsor in accordance with the terms and conditions of this Agreement and attached project addenda. 
 NOW, THEREFORE, for good and valuable consideration, the exchange, receipt and sufficiency of which are acknowledged, the Parties agree as follows: 
  

	1.	SERVICES. 

 1.1 In the event
that the Parties shall reach agreement with respect to a particular clinical research program (each, a “Study”) for a particular molecule that is proprietary to Sponsor (each, a “Study Drug”), the Parties shall
execute a project addendum substantially in the form attached as Exhibit A (each, a “Project Addendum”) for said Study, and such Project Addendum shall be attached and incorporated into this Agreement. Each Project Addendum, along
with this Agreement and the protocol describing such Study (each, a “Protocol”, as more specifically defined in the applicable Project Addendum) shall collectively constitute the entire agreement for the specific Study,
independently from other Project Addenda. No Project Addendum shall be attached to this Agreement without first being executed by the Parties. To the extent any terms set forth in a Project Addendum shall conflict with the terms set forth in this
Agreement, the terms of this Agreement shall control unless it is otherwise specifically set forth in the Project Addendum that certain terms of the Project Addendum shall control. 
 1.2 Kendle shall perform services as set forth in the “Services” section of each Project Addendum attached to this Agreement
(“Services”). Kendle shall provide said Services in strict compliance with this Agreement, the applicable Project Addendum, the applicable Protocol, the written instructions of the Sponsor, Kendle’s Standard Operating
Procedures (“SOPs”) which, if requested by Sponsor in writing, shall be made available to Sponsor for its review, and all applicable national, supranational, state, provincial and local laws, rules, and regulations, including,
without limitation, (a) the Health Insurance Portability and Accountability Act of 1996, and the regulations promulgated pursuant thereto (“HIPAA”); (b) the Federal Food, Drug and Cosmetics Act and the regulations
promulgated pursuant thereto, including, without limitation, 21 C.F.R. Parts 11, 50, 54, 56 and 312; (c) the Declaration of Helsinki; (d) the EU Data Protection Directive 95/46/EC and any applicable national legislation promulgated
thereunder and any and all laws applicable in the countries in which such collection and processing would occur (“Data Protection Legislation”) and (d) the current good clinical practices set forth by any national,
multi-national, supranational or other governmental body with jurisdiction over the applicable Study (the foregoing, collectively, “Applicable Laws”). 
  

 1 of 58 

 1.3 Any and all obligations of the Sponsor which Sponsor desires to transfer to Kendle in
accordance with 21 C.F.R. 312.52 shall be specifically labeled in the Project Addendum as “Transferred Obligations under 21 C.F.R. 312.52”, and Kendle shall assume the responsibility for such transferred obligations hereunder as
“Sponsor” under the Federal Food, Drug and Cosmetic Act. Kendle agrees to carry out diligently all transferred obligations. Sponsor will retain all obligations not specifically transferred to Kendle pursuant to this Section. 
 1.4 In the event that Kendle is requested or required by Sponsor to perform services beyond those which are specifically set forth in a Project
Addendum, any such additional services and an associated compensation schedule must be mutually agreed upon by the Parties, prior to the provision of said services, in writing expressly referencing the applicable Project Addendum. Said mutually
agreed upon writing shall be an addendum to the applicable Project Addendum and the services set forth therein shall be deemed to be Services as the term is used in this Agreement. 
  

	2.	COMPENSATION AND PAYMENT. 

 2.1 Payment for Services, Pass-Through Costs, and Investigator Invoices. 
 (a) For its
performance under this Agreement, Kendle shall receive compensation for Services as set forth in an applicable Project Addendum which shall be incorporated herein by reference. The Parties acknowledge and agree that the total costs for Services
performed and Pass-Through Costs (as defined below) incurred with respect to a particular Project Addendum shall not exceed the figure for total project costs specified in such Project Addendum without the prior written approval of Sponsor.

 (b) Sponsor shall reimburse Kendle for all reasonable, necessary out-of-pocket expenses actually incurred in connection with the
performance of the Services with respect to a Project in accordance with this Agreement and the applicable Project Addendum, including, without limitation, travel expenses incurred in accordance with Kendle’s standard global travel policies,
shipping and postage costs, copying and printing fees, copyright fees, third party drug storage and distribution fees, required Institutional Review Board or similar board or committee fees and other “pass through” expenses identified in
the applicable Project Addendum, including, without limitation, all expenses due and payable to any approved sub-contractor under Section 4.2 hereof (collectively, the “Pass-Through Costs”). 
 2.2 The Parties acknowledge and agree that the Services provided by Kendle may require specific payment, invoicing and currency management
structures which shall be set forth in each applicable Project Addendum. Payment shall be in accordance with such payment, invoicing and currency management structures in each such Project Addendum unless such Project Addendum specifically
references the Basic Payment Structure in Section 2.2(a) below. 
 (a) Basic Payment Structure. Unless specifically stated
otherwise in an individual Project Addendum, Kendle shall submit to Sponsor an itemized monthly invoice describing the Services performed by Kendle with respect to a Study, the charges for such Services and all Pass-Through Costs paid by Kendle.
Each such invoice shall be in a substantially similar format as the payment structure required under the applicable Project Addendum, such that the amounts invoiced can be traced, item by item, to the payments authorized under the applicable Project
Addendum. Invoices reflecting Pass-Through Costs shall be accompanied by appropriate documentation for all such Pass-Through Costs. Sponsor shall pay undisputed amounts of each monthly invoice within thirty (30) days of receipt of said invoice.
If Sponsor disputes any portion of an invoice, then Sponsor shall notify Kendle, and payment for 

  

 2 of 58 

 
disputed amounts shall not be due until the Parties resolve such dispute. The Parties shall initially attempt to informally resolve any such dispute arising
under this Section 2.2 through discussions between representatives of each Party possessing the authority to resolve such dispute. Any such dispute not resolved by such informal discussions within thirty (30) days of the commencement
thereof will be referred to the [CEOs] of the Parties who will actively, reasonably and in good faith meet and negotiate a resolution over the next thirty (30) days. If after conclusion of such negotiation the Parties have failed to resolve
such dispute, such dispute shall be finally settled in accordance with Article 21. 
 2.3 Invoices shall be sent to: 
 ChemoCentryx, Inc. 
 Attn: Accounts Payable

 850 Maude Avenue 
 Mountain
View, CA 94043 
 Or via e-mail to: acountspayable@chemocentryx.com 
 2.4 Any sums due Kendle for additional services performed pursuant to Section 1.4 of this Agreement shall be paid according to the terms of
said Section 1.4. 
 2.5 Except as hereinafter set forth in Section 2.6(b), in the event any Project Addendum, or this
Agreement, is terminated pursuant to Article 3 below, Kendle shall be compensated for all fees for Services actually performed and costs incurred as of the effective date of termination. Additionally, Kendle shall be reimbursed any and all
uncancellable obligations as regards third parties, provided that Kendle shall promptly provide notice and relevant information concerning all such uncancellable third party obligations into which it enters during the term of this Agreement on an
ongoing basis. In the event of termination pursuant to Article 3 below, compensation for partially completed milestones shall be made on a time and materials basis. Any funds held by Kendle which shall be shown by Sponsor to be unearned at the date
of termination shall be returned to Sponsor within forty-five (45) days of termination of this Agreement. 
 2.6 Termination
Costs. 
 (a) In the event that Sponsor suspends, terminates early or reduces in scope a Study, in addition to any and all other
compensation and reimbursement due under this Agreement, Sponsor shall pay to Kendle the non-cancelable costs and expenses which are actually incurred as a result of said early termination or reduction in scope, including by way of example but not
limited to, unforeseen down time and reassignment of Kendle dedicated Study personnel (“Termination Expenses”). Such Termination Expenses shall be supported by competent documentation and shall not exceed the percentage of the total
remaining fees specified in the applicable Project Addendum covering such Study that have not already been paid to Kendle (excluding Pass-Through Costs) that Kendle would have received pursuant to this Agreement had the Study continued at its full
scope until completion. Kendle shall use commercially reasonable efforts to minimize any Termination Expenses. 
 (b) Kendle
acknowledges that early termination by Sponsor of a Project Addendum or this Agreement under Section 3.2(a) may cause Sponsor to incur significant costs associated with transferring performance of the Services to another provider. Accordingly,
if Sponsor terminates a Project Addendum pursuant to Section 3.2(a), the Parties agree that Kendle shall have a single opportunity to re-perform, at Kendle’s sole cost and expense, all such Services which were rendered invalid as a direct
result of the material breach, unless the Parties mutually agree in good faith that Kendle would not be able to re-perform such Services within the timeline and in accordance with the criteria set forth in the relevant Project Addendum. 

 

 3 of 58 

 2.7 Payments to Kendle shall be made to: 
 Kendle International Inc. 
 1200 Carew Tower

 441 Vine Street 
 Cincinnati,
OH 45202 
 Tax ID# 31-1274091 
 2.8 Taxes (and any penalties thereon) imposed on any payment made by Sponsor to Kendle shall be the responsibility of Kendle. 
  

	3.	TERM AND TERMINATION. 

 3.1 The term of this Agreement shall commence as of the Effective Date and end upon completion of the Services unless earlier terminated in accordance with this Article 3. This Agreement shall be renewable upon
terms and conditions mutually acceptable to the Parties hereto. Project Addenda shall commence upon the date of complete execution by the Parties and shall terminate upon the completion of Services specified therein unless earlier terminated in
accordance with Section 3.2. 
 3.2 The Parties may terminate this Agreement or any Project Addendum solely as set forth below.
The termination of this Agreement by either Party shall automatically terminate any and all Project Addenda, unless otherwise agreed to by the Parties in writing. The termination of any or all Project Addenda shall not automatically terminate this
Agreement, unless otherwise agreed to by the Parties in writing. 
 (a) Either Party may terminate this Agreement or any Project
Addendum upon thirty (30) days prior written notice to the other Party of such Party’s material breach of this Agreement or a Project Addendum, provided that the breaching Party does not cure such breach within thirty (30) days of its
receipt of such notice. 
 (b) Either Party hereto may terminate this Agreement immediately upon the occurrence of an
“Insolvency Event” with respect to the other Party. For purposes of this Agreement, “Insolvency Event” shall mean (1) a Party or any of its subsidiaries shall commence a voluntary proceeding seeking liquidation,
reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial
Party of its property, or shall consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it, or shall make a general assignment for the benefit of
creditors, or shall fail generally to pay its debts as they become due, or shall take any action to authorize any of the foregoing; (2) an involuntary case or other proceeding shall be commenced against a Party or any of its subsidiaries
seeking liquidation, reorganization or other relief with respect to it or its debts under bankruptcy, insolvency or other similar law or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any
substantial part of its property, and such involuntary case or other proceeding shall remain undismissed and unstayed for a period of sixty (60) days; or (3) an order for relief shall be entered against a Party or any of its subsidiaries
under the federal bankruptcy laws now or hereafter in effect. 
  

 4 of 58 

 (c) Sponsor may terminate this Agreement or any Project Addendum with or without cause immediately
upon written notice to Kendle, including, without limitation, for any of the following: identification of any medical risk to Study participants; a showing that the Study Drug is not effective; or termination or suspension of the Study by the
regulatory authority having jurisdiction over either Party or the conduct of the Study. 
 3.3 Upon termination of this Agreement or
any Project Addendum pursuant to this Article 3, Kendle shall cooperate with Sponsor to provide for an orderly wind-down of the affected Services provided by Kendle hereunder, and Kendle shall be compensated as set forth in Article 2 above.

 3.4 The obligations of the Parties contained in Articles [***], [***], [***], [***], [***], [***], [***], [***], [***], [***] and
[***] shall survive the expiration or termination of this Agreement. 
  

	4.	PERSONNEL. 

 4.1 Each Project
Addendum shall identify a project team (“Project Team”) that shall be responsible for directing Kendle’s performance of the Study that is the subject of such Project Addendum. The Project Team shall keep Sponsor fully informed
of the progress of the Study that is the subject of the applicable Project Addendum. Kendle shall make no changes to the Project Team for a Study without Sponsor’s prior written consent, such consent not to be unreasonably withheld. In addition
to the foregoing, Kendle shall be obligated at all times to provide a sufficient number of trained clinical research personnel on a given Study to meet the demands of said Study. 
 4.2 Kendle shall not subcontract any Services without the prior written consent of Sponsor, such consent not to be unreasonably withheld. Sponsor
shall have the right to review and pre-approve contracts with any such subcontractors, and such contracts shall, at a minimum, contain terms substantially similar to those in this Agreement with respect to compliance with law, obligations of
confidentiality and non-use of Confidential Information, ownership and allocation of intellectual property rights and indemnification obligations. Any subcontractor and/or affiliate to which Kendle contemplates subcontracting Services shall be named
in each applicable Project Addendum. Upon consent from Sponsor, Kendle shall have the right to provide all or any part of the Services for a Project through an Affiliate of Kendle, in which case such affiliate shall execute the applicable Project
Addendum and shall be deemed to have executed this Agreement and agreed to be bound by the terms and conditions hereof. “Affiliate of Kendle” shall mean an entity which can provide the Services and which controls, is controlled by or is
under common control with Kendle. Notwithstanding anything to the contrary, Kendle remains responsible for the performance of any of its obligations under this Agreement that it delegates to a subcontractor or Affiliate of Kendle. 
 4.3 [***], neither Party shall recruit, hire or employ any personnel of the other who is material to the performance of the particular Study
without the prior written consent of the other Party, except if such recruitment, hiring or employment results directly from a general solicitation for employment placed in a trade journal, newspaper or website. Notwithstanding the foregoing, should
the Sponsor hire any of Kendle’s employees with whom the Sponsor comes into contact as a result of the Study, the Sponsor shall pay Kendle twenty percent (20%) of such employee’s salary as a recruitment fee. 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 5 of 58 

	5.	CONFIDENTIALITY. 

 5.1 During
the term of this Agreement and for a period of ten (10) years thereafter, Kendle agrees to hold all information obtained from Sponsor, whether in oral or written form, or generated or created by Kendle as a result of performing the Services
under this Agreement, including, without limitation, all commercial, scientific, medical and technical information and data relating to Sponsor, a Study Drug or a Study (all such data and information together with any information derived therefrom,
exclusive of computer software and code developed by Kendle unless specifically included by the terms of the relevant Project Addendum, to be referred to herein as “Sponsor Confidential Information”), in strict trust and confidence.

 5.2 During the term of this Agreement and for a period of ten (10) years thereafter, Sponsor agrees to hold all confidential
or proprietary information obtained from Kendle (other than Sponsor Confidential Information), including, without limitation, confidential commercial, scientific, medical and technical information relating to Kendle (hereinafter “Kendle
Confidential Information”), in strict trust and confidence. 
 5.3 “Confidential Information” of a
disclosing Party shall mean Kendle Confidential Information or Sponsor Confidential Information, as applicable. Confidential Information shall not include any information to the extent that such information can be shown by competent written proof to
be: 
 (a) now in the public domain or subsequently enters the public domain through no fault of the receiving Party, or its employees,
agents or approved subcontractors; 
 (b) presently known or becomes known to the receiving Party through its own independent sources;
or 
 (c) received by the receiving Party from any third party not under any obligation to keep such information confidential.

 5.4 Each receiving Party may use or disclose Confidential Information of the disclosing Party to the extent such use or disclosure
is required by law or regulation. If either receiving Party is required to make such a disclosure, then that Party shall notify the other Party to allow such other Party to assert whatever exclusions or exemptions that may be available under such
law or regulation. Additionally, the receiving Party shall reasonably assist the other Party in securing confidential treatment of such Confidential Information, prior to its disclosure, in consultation with that Party (whether through protective
orders or otherwise, and disclose only the minimum necessary to comply with such law or regulation. 
 5.5 Each receiving Party agrees
that it will use any Confidential Information of the disclosing Party only as required to provide the Services and to exercise its rights under this Agreement. Each receiving Party shall not use any Confidential Information of the disclosing Party
for any other purpose without the prior written consent of the disclosing Party. Each receiving Party agrees not to disclose any of the Confidential Information of the disclosing Party to any third party without first obtaining the written consent
of the disclosing Party. Each receiving Party further agrees to take all reasonable steps to ensure that the Confidential Information of the disclosing Party shall not be used by the directors, officers, employees, agents, representatives and
advisors of the receiving Party, except on like terms of confidentiality as aforesaid, and that it shall be kept fully private and confidential by them. 
  

 6 of 58 

 5.6 Each receiving Party agrees that upon the expiration or earlier termination of this Agreement
or, at the disclosing Party’s written request, it shall (and shall cause its directors, officers, employees, agents, representatives and advisors to) return to the disclosing Party all parts of its Confidential Information provided by it in
documentary form and return or destroy any copies thereof made by the receiving Party, its directors, officers, employees, agents or representatives. Notwithstanding the foregoing, each Party may retain one (1) copy of the Confidential
Information of the disclosing Party solely as is reasonably necessary for regulatory purposes, subject to the ongoing obligation to maintain the confidentiality of such Confidential Information. 
 5.7 Each receiving Party acknowledges that disclosure or distribution of the disclosing Party’s Confidential Information, or the use of the
disclosing Party’s Confidential Information contrary to the terms of this Agreement, may cause irreparable harm for which damages at law may not be an adequate remedy, and agrees that the provisions of this Agreement prohibiting disclosure or
distribution of the disclosing Party’s Confidential Information or use contrary to the provisions hereof may be specifically enforced by a court of competent jurisdiction in addition to any and all other remedies available at law or in equity.

 5.8 All Confidential Information containing personal data shall be handled in accordance with all applicable law, including without
limitation HIPAA and the Data Protection Legislation. 
  

	6.	INTELLECTUAL PROPERTY. 

 6.1 Neither anything contained herein nor the delivery of any Confidential Information to Kendle shall be deemed to grant Kendle any right or licenses under any patents or patent applications or to any know-how, technology or
inventions of Sponsor. 
 6.2 Kendle understands and agrees that the underlying rights to the intellectual property and materials that
are the subject of any Study hereunder, including but not limited to all property rights in any Study Drug, belong solely to Sponsor and that data, information, inventions or discoveries (whether or not patentable or registrable under patent,
copyright or similar laws) and materials related to any Study Drug, Study or Protocol or otherwise derived as a direct or indirect result of the performance of the Services, whether generated by Sponsor, Kendle, any Investigators or their agents or
employees, either solely or jointly with others, are the sole property of Sponsor (“Inventions”). Kendle shall disclose to Sponsor in writing any and all Inventions (collectively, “Sponsor Property”) in each case
within forty-five (45) working days of such Invention’s conception or making. All such Sponsor Property, and any information with respect thereto, shall be deemed to be Confidential Information subject to the provisions in Article 5. All
Sponsor Property, and improvements thereto or to other proprietary inventions of Sponsor, shall be the sole and exclusive property of Sponsor, and Kendle shall have no right, title or interest therein. 
 6.3 Subject to Section 6.2, Sponsor acknowledges that Kendle possesses certain inventions, processes, technology, know-how, trade secrets,
improvements, other intellectual property and other assets, including, without limitation, those related to data collection, data management processes, laboratory analyses, analytical methods, procedures and techniques, computer technical expertise
and software (including codes) which have been independently developed before the Effective Date without the benefit of or reliance on any information or materials provided by Sponsor and do not relate to any Study Drug (collectively, the
“Kendle Property”). All Kendle Property and improvements thereto are the sole and exclusive property of Kendle, and Sponsor shall have no right, title or interest therein, except that Kendle hereby grants to Sponsor a worldwide,
royalty-free, non-exclusive license, sublicensable to Sponsor’s affiliates and development and/or commercialization partners (exclusive, however, of other clinical research organizations), to use such Kendle Property internally and solely for
the purpose for 

  

 7 of 58 

 
which the Kendle Property was developed, and on the data for which the Kendle Property was developed, in the course of developing, making, having made,
using, selling, offering for sale and importing Sponsor’s proprietary products incorporating the Study Drug. 
 6.4 Kendle and
its employees and agents shall, upon Sponsor’s request and at Sponsor’s expense, execute such documents and take such other actions as Sponsor deems are reasonably necessary for Sponsor to obtain ownership of Sponsor Property and to apply
for, secure, and maintain patent or other proprietary protection of such Sponsor Property. 
 6.5 Kendle agrees that Sponsor will own
and have the unrestricted free right to use or disclose for all purposes the material, data and information generated or created directly and solely as part of the Services; provided, however, that such unrestricted free right to use
shall not pertain to computer software code unless specifically agreed upon in writing by the Parties. Kendle represents and warrants that it is entitled to deliver the material, data and information to be delivered as part of the Services hereunder
for Sponsor’s free use. 
  

	7.	PUBLICATION. 

 Kendle may not publish
any articles or make any presentations relating to the Services or referring to data, information or materials generated as part of the Services, in whole or in part, without the prior written consent of Sponsor. 
  

	8.	INDEMNIFICATION. 

 8.1 Sponsor
shall indemnify Kendle, its directors, officers, and employees (collectively, “Kendle Indemnitees”) for any and all damages, costs, expenses and other liabilities, including reasonable attorney’s fees and court costs, incurred
in connection with any third party claim, action or proceeding to the extent shown by a court of competent jurisdiction to have arisen from or relate to the Kendle Indemnitees’ performance of the Services under this Agreement or any Project
Addendum; provided, however, that Sponsor shall have no obligation hereunder with respect to any claim, action or proceeding to the extent shown by a court of competent jurisdiction to have arisen from or relate to: (a) the
negligence or intentional misconduct on the part of any Kendle Indemnitee; (b) breach by any Kendle Indemnitee of any of its obligations under this Agreement, including all material and relevant provisions of the Protocol; or (c) violation
by any Kendle Indemnitee of Applicable Laws. 
 8.2 Kendle shall indemnify Sponsor, its directors, officers and employees for any and
all damages, costs, expenses and other liabilities, including reasonable attorney’s fees and court costs, incurred in connection with any third party claim, action or proceeding to the extent shown by a court of competent jurisdiction to have
arisen from or relate to: (a) the negligence or intentional misconduct on the part of any Kendle Indemnitee; (b) breach by any Kendle Indemnitee of any of its obligations under this Agreement, including all material and relevant provisions
of the Protocol; or (c) violation by any Kendle Indemnitee of Applicable Laws. 
 8.3 Any Party obligated to provide
indemnification hereunder shall be entitled, at its option, to control the defense and settlement of any claim on which it is liable, provided that such Party with the obligation to indemnify shall act reasonably and in good faith with respect to
all matters relating to the settlement or disposition of the claim as the disposition or settlement relates to the Party being indemnified. The indemnified Party shall reasonably cooperate in the investigation, defense and settlement of any claim
for which indemnification is sought hereunder and shall provide prompt notice of any such claim or reasonably expected claim to the indemnifying Party. An indemnified Party shall have the right to retain its own separate legal counsel at its own
expense; provided, however, without the 

  

 8 of 58 

 
indemnifying Party’s prior written consent, the indemnified Party shall make no admission to, or any settlement or agreement with, any person or party
who is any manner related to any claim, action or proceeding for which indemnification may be sought hereunder. 
 8.4 Neither Party
nor its affiliates, nor any of their respective directors, officers, employees or agents shall have any liability of any type (including, but not limited to, contract, negligence, and tort liability), for any special, incidental, indirect or
consequential damages, including, but not limited to the loss of opportunity, loss of use, or loss of revenue or profit, in connection with or arising out of this Agreement, any Project Addendum, or the Services contemplated hereunder, even if such
damages may have been foreseeable to such party. In addition, in no event shall the collective, aggregate liability (including, but not limited to, contract, negligence and tort liability) of Kendle and its affiliates and its and their respective
directors, officers, employees and agents under this Agreement or any Project Addendum hereunder exceed the amount of the Budget for a particular Project Addendum from which such liability arose. Notwithstanding the foregoing, the limitations on
liability set forth in this Section 8.4 shall not apply to liabilities arising out of a Party’s indemnification obligations under this Article 8, or to liabilities arising from a Party’s breach of its obligations under Article 5
(Confidentiality) or Article 6 (Intellectual Property) hereof. 
  

	9.	INDEPENDENT CONTRACTOR RELATIONSHIP. 

 The Parties are independent contractors and nothing contained in this Agreement shall be construed to place them in the relationship of partners, principal and agent, employer/employee or joint venturer. Both Parties
agree that they shall neither have the power or right to bind or obligate the other, nor shall either hold itself out as having such authority. 
  

	10.	CONFLICTS. 

 Kendle represents and
warrants to Sponsor that Kendle is not a Party to any agreement which would prevent it from fulfilling its obligations under this Agreement. 
  

	11.	PUBLICITY. 

 Except as required by
law, neither Party shall use the name of the other Party nor of any employee of the other Party in connection with any publicity without the prior written approval of the other Party. 
  

	12.	FORCE MAJEURE/DELAYS. 

 In the event either Party shall be delayed or hindered in or prevented from the performance of any act required hereunder by reasons of strike, lockouts, labor troubles, restrictive government regulations, riots,
insurrection, war, Acts of God, inclement weather or other regulatory reason or cause beyond such Party’s control, then performance of such act shall be excused for the period of such delay. Any timelines affected by such force majeure shall be
extended for a period equal to that of the delay and any affected Study budgets shall be adjusted as appropriate to reflect increases or decreases in costs. Notice of the start and stop of any such force majeure shall be provided to the other Party.

  

	13.	RECORD STORAGE. 

 13.1 During the term of this Agreement, Kendle shall maintain all materials and all other data obtained or generated by Kendle in the course of providing the Services hereunder, including all computerized records and files, in a
secure area reasonably protected from fire, theft and destruction. 

  

 9 of 58 

 
Kendle shall cooperate with any internal review or audit by Sponsor and make available to Sponsor for examination and duplication, during normal business
hours and at mutually agreeable times, all documentation, data and information relating to a Study. 
 13.2 At the expiration or
termination of this Agreement and upon written instruction of Sponsor, all materials and all other data and information obtained or generated by Kendle in the course of providing the Services hereunder shall, at Sponsor’s option, be:
(a) delivered to Sponsor at its offices in Mountain View, CA in such form as is then currently in the possession of Kendle; (b) retained by Kendle for Sponsor for a period of three years; or (c) disposed of, at the direction and
written request of Sponsor, unless such materials are otherwise required to be stored or maintained by Kendle as a matter of law or regulation. Sponsor shall have sole responsibility for the costs of shipping of the materials referred to herein.
Sponsor shall retain and be responsible for the performance of any carrier designated by Sponsor for the shipping of materials. In no event shall Kendle dispose of any materials or data or other information obtained or generated by Kendle in the
course of providing the Services hereunder without first giving Sponsor sixty (60) days prior written notice of its intent to do so. Notwithstanding the foregoing, Kendle may retain one (1) copy of any the materials referred to herein as
are deemed reasonably necessary, by Kendle and Sponsor, for regulatory and legal archival purposes, subject to its ongoing obligation to maintain the confidentiality of such materials. 
  

	14.	DEBARMENT. 

 14.1 Kendle
hereby certifies that it has not been, and covenants that it will not be, debarred, and has not been convicted of a crime which could lead to debarment, under the Generic Drug Enforcement Act of 1992, 21 United States Code Section 306(a) or
(b). In the event that Kendle or any of its officers, directors, or employees under contract to perform services under a Study becomes debarred or receives notice of action or threat of action with respect to its debarment, Kendle shall notify
Sponsor immediately. 
 14.2 Kendle hereby certifies that it has not utilized, and covenants that it will not knowingly utilize, the
services of any individual or entity in the performance of services under this Agreement that has been debarred or that has been convicted of a crime which could lead to debarment under the Generic Drug Enforcement Act of 1992, 21 United States Code
Section 306(a) or (b). In the event that Kendle receives notice of the debarment or threatened debarment of any such individual or entity, Kendle shall notify Sponsor immediately. 
  

	15.	Notices. 

 Any notice required or permitted to be
given hereunder by either Party hereunder shall be in writing and shall be deemed given on the date received if delivered personally or by fax or five (5) days after the date postmarked if sent by registered or certified U.S. mail, return
receipt requested, postage prepaid to the following address: 
  

							
	If to Kendle:	  	Kendle International Inc.	  	If to Sponsor:	  	ChemoCentryx, Inc.
		  	441 Vine Street	  		  	850 Maude Avenue
		  	1200 Carew Tower	  		  	Mountain View, CA 94043
		  	Cincinnati, OH 45202	  		  	Attn: Vice President, Medical and
		  	Attn: General Counsel	  		  	Clinical Affairs
		  	Tel:     1-800-733-1572	  		  	Tel:    (650) 210-2900
		  	Fax:    513-381-5870	  		  	Fax:    (650) 210-2910

  

 10 of 58 

	16.	SEVERANCE. 

 If any one or more
provisions of this Agreement shall be found to be illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby, provided the surviving agreement
materially comports with the Parties’ original intent. 
  

	17.	WAIVER. 

 Waiver or forbearance by
either Party or the failure by either Party to claim a breach of any provision of this Agreement or to exercise any right or remedy provided by this Agreement or applicable law, shall not be deemed to constitute a waiver with respect to any
subsequent breach of any provision hereof. 
  

	18.	ENTIRE AGREEMENT. 

 This Agreement, including any approved Project Addenda, represents the complete and entire understanding between the Parties regarding the subject matter hereof and supersedes all prior negotiations, representations or agreements, either
written or oral, regarding this subject matter, provided, however, that the surviving provisions of that certain Letter of Intent dated August 23, 2006 by and between Kendle and Sponsor shall remain in full force and effect. No
changes or modifications of this Agreement shall be deemed effective unless in writing and executed by the Parties. 
  

	19.	AVOIDANCE OF CONFLICTS OF INTEREST. 

 For any Studies conducted internally by Kendle without the involvement of any third party Sites, Kendle shall complete and shall ensure that all
investigators and other researchers engaged in each such Study shall each individually complete the Disclosure of Financial Interests and Arrangements as attached at Exhibit B and return it to Sponsor. For any Studies conducted by Kendle in
conjunction with third party Sites, Kendle shall ensure that all investigators and researchers engaged in each such Study shall each individually complete a Disclosure of Financial Interests and Arrangements in a form acceptable to Sponsor and
materially similar to the one attached hereto as Exhibit C. All such disclosures shall be referred to as “Disclosures.” Sponsor shall hold such Disclosures in confidence and shall only use such Disclosures in meeting FDA regulatory
requirements under 21 C.F.R. Part 54. Failure to return completed Disclosure(s) to Sponsor may result in Sponsor terminating this Agreement. By completing the Disclosure, Kendle certifies that the Disclosure supplied is truthful and accurate. In the
event that circumstances change during the Study and the Disclosure submitted by Kendle is no longer truthful and accurate, Kendle agrees to promptly submit to Sponsor updated Disclosure(s) reflecting the new circumstances. 
  

	20.	ASSIGNMENT. 

 This Agreement,
including any Project Addendum, may not be assigned by either Party without the prior written consent of the other Party, provided, however, the Parties may assign this Agreement to a successor to the Party’s business interests. Any attempted
assignment of this Agreement not in compliance with this Section 20 shall be null and void. No assignment shall relieve either Party of the performance of any accrued obligation that such Party may then have under this Agreement. This Agreement
shall inure to the benefit of and be binding upon each Party hereto, its successors and permitted assigns, subsidiaries and affiliates. 
  

 11 of 58 

	21.	ARBITRATION. 

 In the event that any
dispute arises hereunder or with respect to the Services to be provided as set forth herein, the Parties agree to submit such dispute to non-binding arbitration by the Judicial Arbitration & Mediation Services, Inc. (J.A.M.S.) or a similar
private judging service employing retired judges; provided, however that disputes regarding the validity, scope or enforceability of patents shall be submitted to a court of competent jurisdiction in the country where such patent has issued. If such
dispute is not resolved through such non-binding arbitration, then either or both Parties shall be free to pursue all remedies available to it under law or equity. 
  

	22.	CONSTRUCTION. 

 No rule of strict
construction will be applied in the interpretation or construction of this Agreement. The Article and Section headings are included in this Agreement merely for convenience of reference, and they are not to be considered part of this Agreement or
used in the interpretation of this Agreement. When used in this Agreement, “including” means “including without limitation.” Whenever a Party’s consent or approval is required under this Agreement, such Party may grant or
deny its consent or approval in its sole and absolute discretion. Subject to Article 12, time is “of the essence” in the performance of obligations under this Agreement. This Agreement is in the English language only, which language shall
be controlling in all respects, and all versions hereof in any other language shall be for accommodation only and shall not be binding upon the parties. In the event of any conflict or ambiguity between this Agreement and any Project Addendum,
Schedules, Exhibits or other document relating to the subject matter, this Agreement will control; provided, however, that in the event of a conflict between the payment, invoicing, or currency management provisions of a Project Addendum and this
Agreement, the payment, invoicing, and currency management provisions in such Project Addendum shall control. In the event of any conflict or ambiguity between any particular Project Addendum and its related Schedules, the applicable Project
Addendum will control. 
  

	23.	COUNTERPARTS. 

 This Agreement may be
executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute a single instrument. Counterparts may be signed and delivered by facsimile, each of which shall be binding when executed.

 IN WITNESS WHEREOF, this Agreement has been executed by the Parties through their duly
authorized officers as of the Effective Date. 
  

									
	ACCEPTED:KENDLE INTERNATIONAL, INC.	 		 	CHEMOCENTRYX, INC.
					
	By:	 	 /s/ Karl Brenkert III
	 		 	By:	 	 /s/ Thomas Schall, Ph.D.

			
	Authorized Representative	 		 	Authorized Representative
					
	Name:	 	Karl Brenkert III	 		 	Name:	 	Thomas Schall, Ph.D.
	Title:	 	Senior Vice President & CFO	 		 	Title:	 	President & CEO
	Date:	 	October 13, 2006	 		 	Date:	 	21 Nov 2006

  

 12 of 58 

 PROJECT ADDENDUM 
 ChemoCentryx, Inc. (“Sponsor”) and Kendle International Inc. (“Kendle”) have entered into a Clinical Research Services Agreement dated October 12, 2006 (“Master Agreement”) which
provides in Section 1.1 that a Project Addendum be entered into by the Parties to set out with specificity the Services to be performed by Kendle and the compensation to be provided by Sponsor to Kendle with respect to a Study to be performed
under the Master Agreement. The terms and conditions set forth herein are pursuant to and governed by the Master Agreement. Capitalized terms used in this Project Addendum shall have the meaning set forth in the Master Agreement. 
 The Master Agreement effective as of October 12, 2006 is hereby incorporated by reference. To the extent any terms or conditions set forth in this Project Addendum
conflict with the terms and conditions of the Master Agreement, the terms and conditions of the Master Agreement shall control, unless specifically set forth otherwise in this Project Addendum. 
 Further, the Parties entered into a Letter of Intent (“Letter Agreement”) effective as of August 23, 2006, under which Kendle performed certain
Preliminary Services (as that term is defined in the Letter Agreement) related to the Study that is the subject of this Project Addendum. In accordance with Section 10(a) of the Letter Agreement, to the extent that any of the Preliminary
Services set forth in the Letter Agreement are included as part of the Services set forth in this Project Addendum and have already been paid for by Sponsor under the Letter Agreement, Sponsor shall not be required to pay any additional sums for
such Preliminary Services. 
 The term of this Project Addendum shall commence on the date set forth on the last page of this Project Addendum
(“Effective Date”) and shall end on the earlier of the following events: (1) the completion of the Services by Kendle; or (b) the expiration or earlier termination of the Master Agreement or the earlier termination of this
Project Addendum. 
  

	 	I.	Description of Services 

 A. Protocol: 
 “A Multinational Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects with Moderate to Severe
Crohn’s Disease.” 
 B. Assumptions 
 The table
below and the endnotes which follow summarize the assumptions used for the key cost drivers for Sponsor’s project. Certain assumption changes may result in a revision in costs. If this situation appears likely, it will be discussed fully with
Sponsor. Notwithstanding the foregoing, as set forth in Section 2.1(a) of the Master Agreement, in no event shall the total costs for the Services performed and the Pass-Through Costs incurred with respect to this Project Addendum exceed the
“Contract Grand Total” set forth in this Project Addendum without Sponsor’s prior written consent. 
 [***] 
 (The remainder of page 13 and pages 14-19 are redacted.) 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 13 of 58 

 [***] 
 Endnotes for Project Assumptions 
 GENERAL: 
 [***] 
 (The remainder of page 20 and page 21 are redacted.) 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 20 of 58 

 [***] 
  

	 	II.	Project Team for the Study 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 22 of 58 

 [***] 
  

	 	III.	Timeline for Performance Services 

 [***]

  

	 	IV.	Description of Transferred Obligations 

 [***] 
 (The remainder of page 23 and pages 24-25 are redacted.) 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 23 of 58 

 [***] 
  

	 	V.	Budget 

 [***] 
 (The remainder of Page 26 and pages 27-28 are redacted.) 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 26 of 58 

 Investigator Payments 
 To manage Investigator Payments, the Parties agree to comply with the following payment procedures: 
  

	1.	Promptly following the Effective Date of this Project Addendum, Kendle shall establish an escrow account (“Escrow Account”) and Sponsor shall deposit US $[***] in such
Escrow Account within thirty (30) days after such Escrow Account has been established. Kendle shall be authorized to draw from such Escrow Account and use such funds to make Investigator Payments solely as permitted under this Project Addendum,
the Master Agreement, and Sponsor’s written instructions. 

  

	2.	Promptly after the balance of the Escrow Account falls below US $[***] (or such other minimum amount that the Parties may agree upon in writing), Kendle shall provide a forecast to
Sponsor showing the amounts estimated in good faith to be due on Investigator Payments for the next sixty (60) days. Sponsor shall deposit such estimated amount in the Escrow Account within fifteen (15) days of receipt of such estimate;
provided, however, that in no event shall the total amount in such Escrow Account exceed US $[***] without the mutual written agreement of the Parties. 

 Optional Budget — Patient Access and Retention 
 If the Optional Services are requested, ChemoCentryx and Kendle
will enter into an amendment under Section 1.4 of the Master Agreement to include the optional services and fees into this Agreement. 
 [***]

  

	**	Estimates. Actual expenses will be billed as pass-through. 

 Additional
work by Kendle, undertaken at the written request of the Sponsor, or the Sponsor’s failure to communicate all relevant policies and procedures on a timely basis or modifications of such policies and procedures once work has begun, will result
in charges over and above the stated contract amounts at Kendle’s hourly rates. 
  

	 	VI.	Schedule of Payment 

  

	A.	Payments 

 Kendle Fees 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 29 of 58 

 [***] 
  

	 Pass Through Expenses 
	 [***] 

 All Pass Through expenses
will be billed in accordance with Article 2 of the Master Agreement. 
  

	B.	Sponsor billing address and billing contact person information: 

  

					
	 Send invoices to:
	 	Remit payments to:	 	
			
	 ChemoCentryx, Inc.
	 	Kendle International Inc.	 	
	 850 Maude Avenue
	 	1200 Carew Tower, 441 Vine Street	 	
	 Mountain View, CA 94043
	 	Cincinnati, OH 45202	 	
	 Attn: Accounts Payable
	 	Attn: Controller	 	
	 Phone: 1-650-210-2900
	 	Phone: 1-800-733-1572	 	

  

	C.	Currency exchange rate fluctuation. 

 1. Since
pricing and subsequent invoicing are denominated in U.S. dollars while at least a portion of expenditure on the services provided will arise in one or more different currencies, and the contract pricing totals do not include a margin to cover
currency exchange rate fluctuations (“CERF”), the parties agree to review CERF’s every three months throughout the term of this Task Order. 
 2. The contract pricing is based on the following exchange rates: 1 US dollar = .787419 Euro = .529296 GBP = 1.127367 CAD. Provided no currency in which expenditure occurs increases or decreases by more than 3% with
respect to the original pricing currency, (same as in 1 above), the review will conclude that no adjustment to the original pricing is required in relation to the services provided to that date. 
 3. Where a CERF between the U.S. dollar and any other currency of expenditure exceeds 3%, one party will have the potential for gain and the other will
have the potential for unacceptable and unintentional loss. Both parties agree that where this occurs it will be necessary to adjust the pricing of the services to eliminate any loss which would otherwise be incurred by the CRO or Sponsor through no
fault of either party. 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 30 of 58 

 4. Sponsor agrees that if a CERF produces an unscheduled loss not specifically included in the contract
price, Sponsor will agree to a positive price adjustment (i.e. a payment to the CRO) in relation to the services affected, with the effect of offsetting this loss in its entirety. 
 D. The CRO agrees that if a CERF produces an unscheduled gain not included in the contract price, the CRO will agree to a negative price adjustment (i.e.
a reduction in price) in relation to the services affected, with the effect of offsetting this gain in its entirety. In the calculation of the adjustments referred to above, the % CERF will be multiplied by the proportion of service pricing that is
denominated in the currencies that have been subject to the CERF, and these services will then be invoiced at the adjusted prices until reviewed by the parties. 
 AGREED TO AND ACCEPTED BY 
  

									
	 Kendle International Inc.
	 		 	ChemoCentryx, Inc.
					
	 Name:
	 	 /s/ Anthony Forcellini
	 		 	Name	 	 /s/ Thomas Schall, Ph.D.

	 Title:
	 	Anthony Forcellini	 		 	Title:	 	President & CEO
		 	VP Strategic Development	 		 	Date:	 	21 Nov 2006
		 	& Corporate Treasurer	 		 		 	
	 Date:
	 	11/30/2006	 		 		 	

  

 31 of 58 

 FIRST AMENDMENT TO PROJECT ADDENDUM 
 THIS FIRST AMENDMENT TO THE PROJECT
ADDENDUM (“Amendment”) is made and entered into as of January 18, 2007 (the “Amendment Date”) by and between KENDLE INTERNATIONAL
INC., with its principal executive offices located at 441 Vine Street, 1200 Carew Tower, Cincinnati, OH 45202 (“Kendle”), and CHEMOCENTRYX, INC., a Delaware corporation with
its principal executive offices located at 850 Maude Avenue, Mountain View, California 94043 (“Sponsor”). PPD and Sponsor may each be referred to individually as a “Party,” and collectively, as
“Parties.” 
 WHEREAS, Kendle and Sponsor entered into a certain Clinical Research
Services Agreement (the “Agreement”) dated October 12, 2006; and 
 WHEREAS,
pursuant to Section 1.1 of the Agreement, the Parties entered into a Project Addendum (the “Project Addendum”) dated November 30, 2006 for the purposes of setting forth the responsibilities and obligations of the Parties
in regards to conducting a certain clinical research program; and 
 WHEREAS, Pursuant to
Section 1.4 of the Agreement, the Parties wish to enter into this Amendment to the Project Addendum for the purpose of modifying the scope of the Services (as that term is defined in Section 1.2 of the Agreement) to be performed by Kendle
pursuant to the Project Addendum upon the terms and conditions set forth herein. 
 NOW,
THEREFORE, for good and valuable consideration contained herein, the exchange, receipt and sufficiency of which are acknowledged, the Parties agree as follows: 
 1. The table setting forth the “Assumptions” in Section I.B of the Project Addendum (“Assumptions”) is deleted in its entirety and
replaced by the table attached to this Amendment as Exhibit A. 
 2. The language set forth in Section II of the Project Addendum
(“Project Team for the Study”) is deleted in its entirety and replaced by the following: “Pursuant to Section 4.1 of the Master Agreement, the individuals identified on Attachment A to this Project Addendum shall serve as
the Project Team for the Study.” Attachment A to the Project Addendum is provided as Exhibit B to this Amendment. 
 3.
The table setting forth the “Critical Milestones” and “Estimated Date” in Section III of the Project Addendum (“Timeline for Performance of Services”) is deleted in its entirety and replaced by the table attached to
this Amendment as Exhibit C. 
 4. The table set forth in Section IV of the Project Addendum (“Description of Transferred
Obligations”) is deleted and replaced in its entirety by the following: 
 [***] 
 (The remainder of page 32 and pages
33-34 are redacted.) 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 32 of 58 

 [***] 
 5. The budget provided in Section V of the Project Addendum (“Budget”) is deleted in its entirety and replaced by the Budget attached hereto as Exhibit D. For purposes of clarity, the sums set forth
in the column titled “Amend#1 Value” represent the total fees for the additional Services that are the subject of this Amendment, and the sums set forth in the column titled “Contract & Amendment 1 Value USD” represent
the total fees for all Services to be performed by Kendle for the Study under the Project Addendum, as amended. Pursuant to Section 2.1(a) of the Agreement, the total costs incurred with respect to the Project Addendum, as amended, shall not
exceed the “Grand Total” provided in the Budget attached hereto as Exhibit D without Sponsor’s prior written approval. In addition, and without limitation on the foregoing, the total Pass-Through Costs (as that term is defined
in Section 2.1(a) of the Agreement) incurred with respect to the Project Addendum, as amended, shall not exceed $[***] without Sponsor’s prior written approval. 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 35 of 58 

 6. The Parties acknowledge and agree that Sponsor has paid Kendle $[***] for Services provided prior to
the Amendment Date. Sponsor shall deduct this amount from the first payment due under the payment schedule provided in Section 7 of this Amendment. 
 7. The table provided in Section VI.A (“Schedule of Payment – Kendle Fees”) is deleted in its entirety and replaced by the following table: 
 [***] 
  

	*	Enrollment percentages are based on a total of 327 patients for Induction period and 423 for Maintenance period. 

 8. The figure “$[***]” in Section VI.A (“Schedule of Payment – Pass Through Expenses”) is deleted and replaced by the figure
“$[***]”. 
 9. Currency exchange rate fluctuation. 
 a) Since pricing and subsequent invoicing are denominated in U.S. dollars while at least a portion of expenditure on the services provided will arise in one or more different currencies, and the contract pricing
totals do not include a margin to cover currency exchange rate fluctuations (“CERF”), the parties agree to review CERF’s every three months throughout the term of this Task Order. 
 b) The contract pricing is based on the following exchange rates: 1 US dollar = .771939 Euro = .506758 GBP = 1.17377 CAD. Provided no currency in which
expenditure occurs increases or decreases by more than 3% with respect to the original pricing currency, (same as in 1 above), the review will conclude that no adjustment to the original pricing is required in relation to the services provided to
that date. 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 36 of 58 

 c) Where a CERF between the U.S. dollar and any other currency of expenditure exceeds 3%, one party will
have the potential for gain and the other will have the potential for unacceptable and unintentional loss. Both parties agree that where this occurs it will be necessary to adjust the pricing of the services to eliminate any loss which would
otherwise be incurred by the CRO or Sponsor through no fault of either party, 
 d) Sponsor agrees that if a CERF produces an unscheduled loss
not specifically included in the contract price, Sponsor will agree to a positive price adjustment (i.e. a payment to the CRO) in relation to the services affected, with the effect of offsetting this loss in its entirety. 
 e) The CRO agrees that if a CERF produces an unscheduled gain not included in the contract price, the CRO will agree to a negative price adjustment (i.e.
a reduction in price) in relation to the services affected, with the effect of offsetting this gain in its entirety. In the calculation of the adjustments referred to above, the % CERF will be multiplied by the proportion of service pricing that is
denominated in the currencies that have been subject to the CERF, and these services will then be invoiced at the adjusted prices until reviewed by the parties. 
 10. The section titled “Optional Budget – Patient Access and Retention” in Section V is deleted in its entirety. 
 11. Notwithstanding anything to the contrary in this Amendment, the Project Addendum, or the Agreement, each of the Services identified in the budget attached as Exhibit D under “Patient Access &
Retention” and those designated as “PAR” in the section on “Pass Through Estimates” shall be considered individually and will only be performed by Kendle upon prior mutual written agreement between the Sponsor and Kendle. In
the event that Kendle performs such Services without Sponsor’s prior written approval, no amounts shall be due to Kendle for such Services. 
 12. Except as specifically set forth herein, all other terms and conditions contained in the Project Addendum shall remain in full force and effect. 
 IN WITNESS WHEREOF, this Amendment has been executed and delivered by the Parties hereto by their duly authorized officers as of the Amendment Date.

  

									
	KENDLE INTERNATIONAL INC.	 	 	 	CHEMOCENTRYX, INC.
					
	 By:
	 	 /s/ Karl Brenkert III
	 		 	By:	 	 /s/ Thomas Schall, Ph.D.

	 Name:
	 	Karl Brenkert III	 		 	Name	 	Thomas Schall, Ph.D.
	 Title:
	 	Senior Vice President & CFO	 		 	Title:	 	President & CEO

  

 37 of 58 

 EXHIBIT A 
 ASSUMPTIONS 
 The table below and the endnotes which follow summarize the assumptions used for the key cost drivers
for Sponsor’s project. Certain assumption changes may result in a revision in costs. If this situation appears likely, it will be discussed fully with Sponsor. Notwithstanding the foregoing, as set forth in Section 2.1(a) of the Master
Agreement, in no event shall the total costs for the Services performed and the Pass-Through Costs incurred with respect to this Project Addendum exceed the “Contract Grand Total” set forth in this Project Addendum without Sponsor’s
prior written consent. 
 [***] 
 (The remainder of page 38 and pages 39-46 are redacted.)

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 38 of 58 

 [***] 
 Endnotes for Project Assumptions 
 GENERAL: 
 [***] 
 (The remainder of page 47 and pages 48-50 are redacted.) 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 47 of 58 

 EXHIBIT B 
 PROJECT TEAM FOR THE STUDY 
 Pursuant to Section 4.1 of the Master Agreement, the following individuals shall
serve as the Project Team for the Study that is the subject of this Project Addendum: 
 [***] 
 (The remainder of page
51 and page 52 are redacted.) 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 51 of 58 

 EXHIBIT C 
 TIMELINE FOR PERFORMANCE OF SERVICES 
 CRO and Sponsor shall cooperate and use their best efforts to meet the
timelines set forth below. 
 [***] 
 (The remainder of page 53 is redacted.) 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 53 of 58 

 EXHIBIT D 
 BUDGET 
 [***] 
 (The remainder of page 54 and pages 55-56 are redacted.)

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 54 of 58 

 [***] 
 **Estimates. Actual expenses will be billed as pass-through 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

 57 of 58 

 Additional work by CRO, undertaken at the written request of the Sponsor, or the Sponsor’s failure to communicate
all relevant policies and procedures on a timely basis or modifications of such policies and procedures once work has begun, will result in charges over and above the stated contract amounts at CRO’s hourly rates. 
  

 58 of 58

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]